Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (381-390 of 692) with videos related to

Pageof 70
Sort By:
Journal of the National Cancer Institute|February 26, 1999
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancerH I Scher, W M Kelly, Z F Zhang, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2010
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancerDana Rathkopf, Bryan Y Wong, Robert W Ross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz, M Galsky, H I Scher, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancerL Sepp-Lorenzino, G Tjaden, M M Moasser, et al.
European Urology|August 20, 2013
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survivalDaniel C Danila, Aseem Anand, Nikolaus Schultz, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
International Journal of Cancer|April 1, 2005
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccinationPolly D Gregor, Jedd D Wolchok, Vandana Turaga, et al.
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Cancer Research|September 14, 2012
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumorsNicholas Mitsiades, Clifford C Sung, Nikolaus Schultz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trialCharles J Ryan, Arturo Molina, Jinhui Li, et al.
Pageof 70

Showing results (381-390 of 692) with videos related to

Sort By:
Pageof 70
Journal of the National Cancer Institute|February 26, 1999
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancerH I Scher, W M Kelly, Z F Zhang, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2010
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancerDana Rathkopf, Bryan Y Wong, Robert W Ross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz, M Galsky, H I Scher, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancerL Sepp-Lorenzino, G Tjaden, M M Moasser, et al.
European Urology|August 20, 2013
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survivalDaniel C Danila, Aseem Anand, Nikolaus Schultz, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
International Journal of Cancer|April 1, 2005
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccinationPolly D Gregor, Jedd D Wolchok, Vandana Turaga, et al.
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Cancer Research|September 14, 2012
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumorsNicholas Mitsiades, Clifford C Sung, Nikolaus Schultz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trialCharles J Ryan, Arturo Molina, Jinhui Li, et al.
Pageof 70